All data are based on the daily closing price as of November 22, 2024
t

Torii Pharmaceutical

4551.TSE
30.76 USD
0.49
+1.62%

Overview

Last close
30.76 usd
Market cap
864.58M usd
52 week high
30.76 usd
52 week low
22.43 usd
Target price
26.08 usd

Valuation

P/E
24.0543
Forward P/E
N/A
Price/Sales
2.2742
Price/Book Value
1.111
Enterprise Value
582.03M usd
EV/Revenue
1.5305
EV/EBITDA
12.9589

Key financials

Revenue TTM
380.29M usd
Gross Profit TTM
151.11M usd
EBITDA TTM
44.91M usd
Earnings per Share
1.21 usd
Dividend
N/A usd
Total assets
944.38M usd
Net debt
-35.04M usd

About

Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; CORECTIM, a topical janus kinase (JAK) inhibitor; and allergen immunotherapy tablets comprising CEDARCURE and MITICURE. In addition, it is engaged in real estate rental business. The company markets its products primarily through medical representatives for medical professionals. The company has a collaboaration with ALK-Abelló A/S to develop, market and distribute ALK's allergy immunotherapy tablet for the treatment of grass pollen allergy. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc.
  • Symbol
    4551.TSE
  • Exchange
    TSE
  • Isin
    JP3635800000
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Goichi Matsuda
  • Headquarter
    Tokyo
  • Web site
    https://www.torii.co.jp
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top